In 1987, fewer than one in five American adults were obese, and by 1999, obesity was responsible for more than 300,000 excess ...

Nearly two dozen women across the nation have filed lawsuits against a pharmaceutical giant over a contraceptive linked to a ...

Pfizer trades at a 21.7% discount to peers on a 1-yr forward P/E basis, which is a point for the bullish arguments. Find out ...

We recently compiled a list of the 13 Best Dividend Stocks to Buy Under $50. In this article, we are going to take a look at ...

Pfizer stock has been weighed down lately, amid falling revenues and margins. The demand for the Covid-19 vaccine has taken a ...

Pfizer Inc. closed $4.92 short of its 52-week high ($31.54), which the company reached on July 30th.

Twenty-eight years after the incident, survivors lament how their lives have been negatively altered, writes VICTOR AYENI In ...

Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

One of Pfizer's recently acquired revenue sources, Padcev, earned approval to treat newly diagnosed bladder cancer patients ...

Pfizer on Tuesday said it does not expect the Trump administration to make major changes to vaccine policy next year even as ...

Pfizer yields 6.53% and trades at 9x earnings, while Altria offers 7.58% at 10.1x earnings. Pfizer's troubling 221% payout ...

Pfizer shares rose Tuesday morning after the pharmaceutical company affirmed its full-year 2024 projections and issued 2025 ...